Back to search results

MOUD Plus Pilot: Counseling and Peer Support for Opioid Use Disorder

This pilot study is looking at ways to help people with opioid use disorder (OUD) and other medical conditions stay on their buprenorphine treatment and engaged in primary care. It compares two approaches: "Treatment As Usual," which includes regular primary care visits and buprenorphine prescribing, and the "MOUD Plus" Intervention. The MOUD Plus Intervention adds addiction counseling and referrals to community peer support to the usual care. The study aims to see if MOUD Plus can improve how long people stay on buprenorphine and how well they engage with their primary care. You may be able to join if you are 18 or older and have an OUD-related diagnosis. The study is currently unclear on its recruitment status.

Study design
This is a pilot randomized controlled trial with 70 participants. It compares the "MOUD Plus" intervention to "Treatment As Usual."
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants' retention on MOUD will be assessed at 2 months, 3 months, and 6 months after joining the study.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06837662

The MOUD Plus Pilot: Counseling and Peer Support to Support Retention for Medically Complex Patients With Opioid Use Disorder Seen In Primary Care

Recruiting
NAAges 18+InterventionalSupportive care
Oregon Health and Science University
~70 participants
Updated 2026-02-25 on ClinicalTrials.gov
What's tested:MOUD "Plus" Intervention (treatment as usual + coordinated counseling and referral to community based peer)Treatment As Usual (primary care with low threshold MOUD prescribing)

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Retention on MOUD
Measured over assessed at 2 month, 3 months, and 6 month post enrollment

Conditions

Opioid Dependence
Substance Abuse Disorders
Complex Medical Patients
Primary Care Patients With Chronic Conditions

Explore related trials

Complex Medical PatientsOpioid Use Disorder

Where it's being run

1 sites across 1 states
Oregon1

Study leadership

  • Brian Chan, MD MPH · PRINCIPAL_INVESTIGATOR · Oregon Health and Science University

Who to contact

Study Coordinator
[email protected]
503-346-3043
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patient participants 18 years and older
Have an OUD-related diagnosis (e.g. Opioid Use Disorder in remission, Opioid Dependence, Opioid Abuse, Substance Use Disorder - opioids, etc.), or have used fentanyl or heroin over the past 30 days
Who meet at least one of the following criteria:
Present to primary care at Central City Concern (CCC) within 8 weeks of starting or re-starting a treatment episode (defined as starting MOUD after not having received prescribed MOUD in an outpatient setting for OUD in the prior 30 days).
Who present to primary care at CCC and are not seeking treatment with MOUD and have not engaged in counseling services (e.g. harm reduction counseling) in the prior 30 days
Have been receiving MOUD in prior 30 days but had a return to use (used fentanyl or heroin) within the past 30 days
Medical complexity (e.g. self-reported or verified in patient's electronic health record)
Have access to phone and/or computer for follow-up activities
Desire to engage in counseling and/or peer services

Exclusion

Patient participants who present for addiction treatment but are ineligible to receive on-going services at Central City (i.e. they have existing primary care at another location, or are currently receiving opioid use disorder treatment at another clinic, such as methadone clinic) may not participate in the study.
Patient participants who are not able to verbally consent may not participate in the study.
Patients who do not have addiction to opioids may not participate in the study.
Patients who participated in Aim 2 would not be eligible for Aim 3
Patients who lack stable phone access may not participate in the study.

What this trial measures

  • Retention on MOUDassessed at 2 month, 3 months, and 6 month post enrollment

    Retention is defined as a composite measure assessed at follow-up on whether they report being prescribed and taking MOUD, and how days since the last follow-up they have been on MOUD, confirmed by chart review.